This is a Phase 1 study testing a new drug called NM1F, by itself and with pembrolizumab (Keytruda®), for people with advanced solid tumors that have spread or cannot be removed. This includes cancers like ovarian cancer, melanoma, triple-negative breast cancer, and colorectal cancer. The main goals are to see how safe NM1F is, what side effects it might cause, and how your body handles it. Researchers will also look for early signs that the treatment might be working against the cancer. You can join if you are at least 18 years old and your cancer has progressed after standard treatments, or if you cannot tolerate those treatments. This study is currently looking to enroll about 38 participants.

Study design

This is a Phase 1, open-label study, meaning you and your doctors will know which treatment you are receiving. It will enroll about 38 participants.

What's involved

The study involves a screening period of up to 28 days, a treatment period of 1 to 2 years, or until treatment stops, and a follow-up period.

Compensation

Not stated in the trial record.

Follow-up

Your safety will be monitored from screening until 30 days after your last dose of treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.